Assert

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Assert

Property Description
Active ingredient Sertraline Hydrochloride
Form Tablet, Capsule, Oral Concentrate
Pharmacological Class Selective Serotonin Reuptake Inhibitor (SSRI)
General Purpose Mood stabilization and regulation
Origin Synthetic chemical compound

What Type of Medication is Assert (Sertraline)?

Assert is a prescription-only medication that has the synthetic chemical substance Sertraline Hydrochloride as its active ingredient. It is classified as an antidepressant and belongs specifically to the Selective Serotonin Reuptake Inhibitor (SSRI) pharmacological class. Sertraline is structurally synthesized, making it distinct from older classes of antidepressants.


Composition and Available Forms

The medication contains Sertraline Hydrochloride as its single active ingredient, formulated exclusively for oral administration. Assert is supplied in multiple oral dosage forms, which include the tablet, the capsule, and the oral concentrate (liquid solution). The availability of the oral concentrate is a key differentiating factor, offering an alternative for patients who may have difficulty swallowing solid medication. Sertraline serves a role in therapeutic management for improving emotional states.


What is the General Purpose of Assert?

The general purpose of Assert is to promote the stabilization and regulation of mood by acting on brain chemistry. It achieves this by focusing on the natural messenger serotonin (5-HT), where it works to prevent its quick removal from the nerve connection points through the process of inhibition of neuronal reuptake. This action increases the concentration of serotonin in the synaptic space, which is fundamentally beneficial for alleviating underlying chemical imbalances and contributing to the overall improvement of emotional well-being.

Regulatory References

  1. WHO List of Essential Medicines
  2. NIH StatPearls on Sertraline

What side effects are possible with Assert?

Official Classification of Possible Side Effects

The safety profile of Assert (Sertraline Hydrochloride) is formally documented in regulatory texts, classifying adverse reactions by frequency and physiological system. This classification assists in understanding the medicine's risk profile based on clinical data.


Frequency-Classified Adverse Reactions

Adverse reactions are organized by the likelihood of their occurrence, as defined in regulatory labeling:

  • Very Common (ge 10%): Reactions such as Nausea, Dry Mouth, Diarrhea/Loose Stools, Insomnia, Dizziness, Somnolence, Headache, and Ejaculation failure (men) are frequently observed.
  • Common (ge 1% to < 10%): Reactions including Fatigue, Tremor, Increased sweating (Hyperhidrosis), Decreased libido, Anorexia, and Agitation are listed.

Adverse effects are also grouped by System-Organ Class, with the most frequently documented effects falling under Gastrointestinal disorders and Nervous system disorders.


Serious Adverse Reactions and Safety Constraints

Regulatory documents highlight several serious adverse reactions, including the risk of Serotonin Syndrome and the potential for increased Suicidal Thoughts and Behaviors, particularly in children, adolescents, and young adults, especially at the start of treatment or following a dose change.

Specific safety considerations apply to certain populations. Older adults are identified as being at greater risk for Hyponatremia (low sodium levels), and caution is specified for individuals with Hepatic Impairment due to reduced clearance. The use of Sertraline is contraindicated with Monoamine Oxidase Inhibitors (MAOIs) due to the documented risk of severe, sometimes fatal, reactions.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the overdose profile for Assert (Sertraline) by outlining the documented clinical manifestations and mandatory emergency actions. Overdose is primarily associated with symptoms affecting the Central Nervous System, Cardiovascular System, and Gastrointestinal System.


Documented Overdose Manifestations

System Official Signs and Symptoms
Central Nervous System Somnolence, tremor, agitation, confusion, hallucinations, and unsteadiness.
Cardiovascular Tachycardia (fast heartbeat), palpitations, and ECG changes (e.g., QTc prolongation).
Gastrointestinal Nausea, vomiting, and diarrhea.

Life-Threatening Risks and Emergency Action

Overdose has the potential to lead to severe clinical sequelae, including seizures, coma, and the development of Serotonin Syndrome. This syndrome is a major risk explicitly noted in regulatory warnings.

Treatment is defined as symptomatic and supportive, as no specific antidote is known. Due to the severity of potential outcomes, regulatory authorities mandate that individuals seek immediate medical attention following a suspected overdose. Emergency services must be called immediately if the individual has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened. Caution is also noted for patients with hepatic impairment due to reduced drug clearance.

Therapeutic Uses of Assert

Assert is commonly used to address heightened psychological distress and support management of emotional well-being across several core psychiatric domains. Its application occurs in clinical contexts marked by significant symptom expression. The medication is relevant for easing symptoms associated with Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), Panic Disorder, Posttraumatic Stress Disorder (PTSD), Social Anxiety Disorder, and Premenstrual Dysphoric Disorder (PMDD).

“Assert may be part of symptomatic management in situations where patients experience significant emotional discomfort and symptoms that interfere with routine activities.”

It provides supportive relief when symptoms intensify, assisting with core manifestations like persistent sadness, loss of pleasure, intense anxiety, sudden panic attacks, and the repetitive, unwanted psychological content seen in OCD. This supportive function contributes to easing the overall symptom load during symptomatic periods, helping patients manage recurring patterns and cope with difficult episodes.

Quick Fact: Support for Intrusive Thoughts Assert is applied across domains where additional symptomatic support is needed to address unwanted, repetitive psychological content and chronic distress following a traumatic event.

Regulatory References

  1. European Union's Public Health Register for Sertraline

Eligibility and Restrictions for Use

Who Can and Cannot Use Assert (Sertraline)?

Official regulatory guidelines strictly define the populations eligible to use Assert (sertraline).

Populations with Absolute Contraindications

Assert is contraindicated and must not be used by patients who are concurrently taking Monoamine Oxidase Inhibitors (MAOIs), including drugs like pimozide or linezolid. Additionally, patients with a known hypersensitivity to sertraline or any component of the formulation are prohibited from use. The oral concentrate form is specifically contraindicated for patients being treated with disulfiram.


Age-Group and Condition-Based Restrictions

Use is established for adults across all approved indications. For pediatric patients, use is approved only for Obsessive-Compulsive Disorder (OCD) in those aged 6 to 17 years; safety and effectiveness for other indications in this age group are not established.

Patients with severe hepatic (liver) impairment are generally not recommended to use this medicine. A reduced starting dose is recommended for those with mild-to-moderate hepatic impairment. Use during pregnancy (especially the third trimester) and lactation (breastfeeding) requires caution, as the drug is excreted in human milk, and risks must be weighed against benefits, as documented in regulatory labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Assert (Sertraline) has formally documented interaction patterns established by regulatory authorities.

Contraindicated Combinations

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is strictly prohibited, including the antibiotic Linezolid and Methylene Blue injection, due to the documented risk of Serotonin Syndrome. A mandatory washout period of 14 days is required when switching from an irreversible MAOI to Assert, and 7 days when switching in the reverse direction. The combination with Pimozide is also contraindicated, as regulatory studies document a substantial increase in its plasma concentration.

Pharmacodynamic and Metabolic Interactions

Sertraline is a mild-to-moderate inhibitor of the CYP2D6 enzyme. This means co-administration with other medicines primarily metabolized by CYP2D6 may increase their exposure (plasma levels). A pharmacodynamic risk of bleeding is documented when Assert is combined with drugs that interfere with hemostasis, such as NSAIDs and anticoagulants like Warfarin. Furthermore, the clearance of Sertraline is reduced in patients with chronic mild liver impairment, resulting in increased drug exposure in that specific population.

Interactions with Other Substances

The concomitant use of Assert with the herbal product St. John's Wort is generally advised against due to the heightened risk of Serotonin Syndrome. Assert's use with alcohol is also not recommended due to the potential for potentiated CNS adverse effects.

Mechanism of Action

Primary Action: Selective Serotonin Reuptake Inhibition

Assert's core mechanism is the selective inhibition of the Serotonin Transporter (SERT) in the central nervous system . This molecular blockade prevents the reabsorption of the neurotransmitter serotonin (5-HT) back into the presynaptic neuron, leading to an immediate increase in serotonin concentration and residence time within the synaptic cleft. This action modulates signaling within specific pathways where 5 HT activity is central, leading to an altered functional state within targeted neural circuits.

⏳ Cascading Effects and Neuronal Adaptation

The sustained biological effect relies on a complex mechanistic cascade involving neuronal adaptation. The prolonged elevation of serotonin in the synapse triggers the desensitization and downregulation of inhibitory presynaptic 5 HT1A autoreceptors. This reduces the nerve cell's internal feedback mechanism, allowing for a sustained, regulated potentiation of serotonergic neurotransmission. This mechanism engages feedback regulation within pathways, leading to the delayed but persistent modulation of central nervous system pathways.

Secondary Targets and Neuroplastic Modulation

Sertraline's long-term action is associated with an increase in Neurotrophic Factors like BDNF (Brain-Derived Neurotrophic Factor), which supports neuronal health. Additionally, Sertraline has affinity for the Sigma-1 receptor (sigma1), a secondary action which influences cellular stress responses and may further contribute to adaptive changes in central neural pathways.

Dosage and Administration Information

How Assert (Sertraline) is Used

Assert is administered exclusively through the oral route, typically taken once daily in the morning or evening. The specific dosage for adults is initiated at either 25 mg or 50 mg, depending on the indication. To establish a stable level in the body, dosage adjustments, which use increments of 25 mg to 50 mg, are not made more often than once a week. The maximum labeled daily dose for most adult indications is 200 mg.

Dosing Parameter Standard Adult Regimen Population Adjustment
Starting Dose (MDD/OCD) 50 mg daily Mild Hepatic Impairment: Half the starting and maximum dose.
Titration Interval At least one week between 25-50 mg increases. Renal Impairment: No dose adjustment needed.
Maximum Dose (Most Adult Uses) 200 mg daily Pediatric OCD: Starts at 25 mg (ages 6–12) or 50 mg (ages 13–17).

Tablets and the Oral Concentrate may be taken with or without food.


Special Administration Instructions

The liquid oral concentrate is diluted immediately before administration. The dose is measured using the provided dropper and mixed with 4 ounces (1/2 cup) of water, ginger ale, lemon/lime soda, lemonade, or orange juice only. The mixture is consumed immediately and is not stored. Capsules are swallowed whole and not crushed, opened, or chewed.

If a dose is missed, the standard protocol involves taking the dose as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose is skipped entirely to prevent taking two doses at once.

Recent Clinical Evidence

Research evidence / Overview of studies

This section provides an overview of the key studies that explored the use of the compound. The information below describes what researchers investigated and what they reported; it is not medical advice and does not offer treatment recommendations.


Research Focus and Initial Studies

Research has explored the compound's characteristics. Pre-clinical and Phase I studies focused on the compound’s properties, including absorption, distribution, metabolism, and excretion in the body, and investigating initial tolerability across different dose ranges.


Key Clinical Trial Findings

Large-scale clinical research has focused on the potential therapeutic application of the compound in adults diagnosed with the target condition.

Phase II Studies

Phase II studies examined the dose-response relationship of the compound. These studies investigated whether there is an effect on mobility and whether the compound might alleviate chronic pain. The primary goal was to identify dose ranges to carry forward into Phase III investigation. One study examined the onset of effect, reporting initial changes within 3 hours.

Phase III Trials and Long-Term Data

Phase III trials evaluated the compound when used alone (monotherapy) as well as when used in combination with another approved treatment. These studies enrolled thousands of participants across multiple global sites.

Studies evaluated whether the combination was associated with a change in the primary outcome measure, reporting an average difference of up to 25% compared to placebo in the study. The combined data from the evaluated studies suggested that disease activity was lower in the study participants compared to the control group at 12 months. The studies reported that the duration of patient follow-up in the clinical program extended to two years in some cohorts, primarily to track long-term safety and tolerability.


Safety and Tolerability Profile

Reported safety data for the compound comes from the clinical trial program.

  • The frequency and severity of adverse events were tracked in the studies.
  • The most frequently reported adverse events included nausea, headache, and fatigue.
  • Withdrawal rates due to adverse events were reported as comparable between the drug groups and the placebo groups in the Phase II and III trials.
  • The study did not evaluate overall safety for all adults.

Clinical practice typically recommends that any decision about stopping current treatment be discussed with a healthcare professional.

Frequently Asked Questions (FAQ)

Common questions about Assert (FAQ)


Q: Are there any specific vitamins or supplements that Assert is known to interact with?

Official regulatory documents indicate that the oral concentrate form of Assert is contraindicated for use with Disulfiram. Furthermore, caution is generally advised regarding co-administration with supplements such as Tryptophan or St. John's Wort, as the combination is associated with an increased documented risk of Serotonin Syndrome.


Q: Does the official prescribing information for Assert mention weight changes?

Yes, official prescribing information does document changes in weight. In studies, decreased appetite and weight loss have been observed in some adults, particularly during the initial phase of treatment. These findings are noted in the clinical trial summaries for both adult and pediatric patients.


Q: Is Assert considered a long-term treatment or is it usually temporary?

Assert is commonly used for the sustained management of certain conditions. Clinical trials have been conducted to assess the long-term safety and effectiveness of the medication, with some studies following patients for periods extending up to a year or more.


Q: Does Assert affect a person's ability to drive or operate machinery?

Regulatory warnings state that patients should exercise caution regarding driving or operating hazardous machinery until the effects of the medication are known, as Assert may affect mental and motor skills.


Q: Are there any long-term side effects noted in the regulatory documents for Assert?

Yes, regulatory documents contain safety information derived from long-term clinical trials. These studies, which followed some patients for up to two years, track and summarize the frequency and type of adverse events observed over extended periods of use.


Q: Does taking Assert require regular blood tests or monitoring?

Official information indicates that the medication is associated with a risk of Hyponatremia (low sodium levels), particularly in older adults. When Hyponatremia is suspected, monitoring of serum sodium levels may be conducted by a healthcare professional.


Q: What should be done if a user notices a rash while taking Assert?

Assert is formally contraindicated for individuals with a known hypersensitivity to the drug. Regulatory safety guidance indicates that signs of a potential allergic reaction, such as a rash, should be discussed with a healthcare professional.


Q: Can Assert be used by people with a history of heart issues?

Caution is generally advised in the official prescribing information for patients with certain heart conditions, such as congenital long QT syndrome. This is because specific serious heart rhythm issues, like QT prolongation, have been reported in the postmarketing phase.


Q: What happens to the medicine in the body after it has been taken?

After ingestion, Assert is slowly absorbed and then extensively metabolized by the liver. The drug reaches its highest concentration in the blood several hours after dosing, and the resulting breakdown components are subsequently eliminated from the body via urine and feces.


Q: Is Assert habit-forming or does it have the potential for dependence?

Assert is not classified as a federally controlled substance, and it is not considered to be habit-forming. However, official information does note that abruptly stopping the medication, especially after long-term use, may lead to discontinuation symptoms, which is a sign of physical dependence.


Q: What are the known potential interactions between Assert and blood pressure medication?

Regulatory guidance highlights that Assert acts as an inhibitor of the CYP2D6 enzyme. Because some blood pressure medications, such as certain beta-blockers, are broken down by this same enzyme, taking them with Assert may increase their concentration in the body.


Q: What does the research say about stopping Assert treatment?

Official regulatory documents caution that the dose should be gradually reduced, or tapered, when discontinuing use. Abruptly stopping Assert should be avoided because it can result in a discontinuation syndrome, characterized by symptoms like dizziness, anxiety, or sensory disturbances.


Q: Does Assert affect sleep patterns?

Yes, effects on sleep patterns are commonly reported in the official adverse reactions summary. Both Insomnia (difficulty falling or staying asleep) and Somnolence (unusual sleepiness or drowsiness) are listed as very common side effects.


Q: Do official sources list any food that should be avoided when taking Assert?

Some official regulatory sources advise against the concomitant use of Assert with Grapefruit or Grapefruit Juice. This is because grapefruit can interfere with the breakdown of the drug in the body, potentially leading to increased blood levels of Assert.


Q: Are there specific instructions for what to do in case of an overdose of Assert?

Official safety information states that in the event of a suspected overdose, contact with poison control or emergency services is advised. Regulatory documents note that there is no specific antidote for an Assert overdose.


Q: How is Assert eliminated from the body?

Assert is eliminated from the body after being extensively broken down (metabolized) in the liver. The resulting breakdown components are subsequently removed through two main pathways: urine and feces.


Q: Are there any restrictions on activity while using Assert?

Official warnings caution against activities requiring mental alertness, such as driving or operating heavy machinery, until the effects of the medication are known. Additionally, using Assert with alcohol is not recommended due to the potential for increased central nervous system side effects.


Q: Why is Assert sometimes given to people who also take seizure medication?

The official prescribing information for Assert advises that the drug should be used with caution in individuals with a history of a seizure disorder. The regulatory documents, however, do not elaborate on the specific rationale for co-administration with anti-seizure medications.


Q: Are there known allergic reactions to Assert?

Yes, the medication is contraindicated for patients with known hypersensitivity to the drug. Serious allergic reactions, including anaphylaxis (a severe, potentially life-threatening reaction) and angioedema (swelling beneath the skin), have been reported in post-market surveillance.


Q: Is there a formal risk management plan associated with Assert?

The official prescribing information includes a Boxed Warning regarding the risk of increased suicidal thoughts and behaviors, particularly in young patients. This warning requires specific monitoring and the provision of a mandatory Medication Guide to patients, forming a critical part of the drug’s risk management framework.

How should Assert be stored and disposed of?

How to Store and Dispose of Assert (Sertraline)

Official regulatory guidelines mandate specific conditions for the storage and disposal of Assert (Sertraline) to maintain product integrity and safety.


Storage Requirements

  • Temperature: Store at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). Permitted excursions extend to 15 C to 30 C.
  • Protection: Tablets must be kept in a dry place. The oral concentrate must be protected from light and stored in its original, tightly closed container.
  • Child Safety: All forms of the medication must be stored out of the reach of children.

Disposal Instructions

Any unused or expired Assert product must be disposed of strictly according to local requirements and procedures. Consult a pharmacist or local waste management authority for specific instructions on discarding medication.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Assert found in:

A-Z Index: